The views expressed on this podcast are those of the participants, not Aroids News.

So I believe dealing with obesity can be a very meaningful and a sizable part in actually reverting the trend and the burden on the healthcare system.

And I do think we can articulate that and also get pay us to buy into that.

That was Nova Nordisk CEO Lars Furgard Jorgensen, speaking to me for a Reuters newsmaker

last year about the strength of obesity drugs and why insurance companies and governments are likely to pay for them.

Welcome back to the views room. I'm Amy Donnellin. And I'm Anita Ramoswamy. And this week, we are digging

into the fascinating world of obesity drugs. Me and my colleague Rob Seren have been writing about this

market for the past few years, delving into how these drugs

might revolutionize the world and upend established industries like the fast food sector.

So stay tuned for the views room, the weekly podcast from Reuters Breaking Views,

where Amy and I talk to our fellow columnists about the big stories of the week.

And we're coming to you from London and New York.

The obesity drug craze is continuing at an insatiable rate. Noban Nordisk, the Danish insulin giant, which was the first company to get approval to sell its remedy in the US, is now facing competition from Eli Lilly.

So Anita, we are joined by your colleagues over in the US, Lauren Silva Lachlan, the US editor of breaking views, and Rob Siren, who is covering pharma stateside.

Hi, good morning.

We have a lot to chat about today.

So Rob, Amy, Lauren, I know you've all written about this market in different ways.

And Rob, you have specifically been covering a lot of the implications for the U.S. market.

And just given there's so much talk about obesity being a big problem here in the U.S., I was wondering if you could lay it out for us.

What is the scope of the problem in

terms of U.S. obesity rates? Well, consider that 40% of American adults are obese, which is,

you know, a lot of people. You know, 100 million people are so in the United States. And obesity

...